⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 29, 2015JAMA DermatologyOpen Access

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Martina Sanlorenzo Igor Vujic Adil Daud Alain P. Algazi Matthew A. Gubens Sara Alcántara Luna Kevin Lin Pietro Quaglino Klemens Rappersberger Susana Ortiz‐Urda

View Full Paper

Ask AI

Bookmark

Share

Abstract

Pembrolizumab therapy was associated with cutaneous AEs in 42% of patients. The development of cutaneous AEs, especially of hypopigmentation in patients with melanoma, could point toward better treatment response.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sanlorenzo et al. (2015) studied this question.

synapsesocial.com/papers/69df22db9b582f29b9591809 https://doi.org/10.1001/jamadermatol.2015.1916

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Interleukin 5 Inhibitors and Steroid-Sparing Effects in Drug Reaction With Eosinophilia and Systemic SymptomsJAMA Dermatology · Wed,
2Evaluating the Performance of Melanoma Risk Prediction ModelsJAMA Dermatology · Wed,
3Low-Concentration Topical Trametinib for Refractory Darier DiseaseJAMA Dermatology · Wed,
4Infantile HemangiomasJAMA Dermatology · Wed,
5Cancer Risk in Patients With Overall and Site-Specific Lichen PlanusJAMA Dermatology · Wed,

More from JAMA Dermatology

Global Burden of Acne Vulgaris From 1990 - 2023 and Forecasts to 2050Wed,
Papulonodules and Lymphadenopathy in a Man in His 30sWed,
Device-Free Auricular Acupressure for RosaceaWed,
Inflation-Adjusted Medicare Reimbursement for Common Dermatologic ProceduresWed,
Giant Plexiform Neurofibroma in Neurofibromatosis Type 1Wed,